(Adds details about existing treatments, share price)
Dec 15 (Reuters) - The U.S. Food and Drug Administration approved Aclaris Therapeutics Inc's topical drug to treat a common kind of skin growth called seborrheic keratoses, the company said on Friday.
The drug, Eskata, would be the first FDA-approved non-invasive treatment for the condition, Aclaris said.
Seborrheic keratoses are non-cancerous skin growths that affect more than 83 million American adults, according to Aclaris.
Current therapies for treating such skin lesions include cryosurgery, burning, cutting or scraping all generally painful options that may also cause pigmentation and infection.
Eskata is expected to be commercially available in the spring of 2018.
Shares of Malvern, Pennsylvania-based Aclaris rose 9.2 percent to $24.72 in premarket trading. (Reporting by Divya Grover in Bengaluru; editing by Sai Sachin Ravikumar)